Nuvectis Pharma (NVCT) Net Cash Flow (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Net Cash Flow data on file, last reported at -$6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 157.4% year-over-year to -$6.5 million; the trailing twelve-month figure through Mar 2026 stood at -$4.7 million (down 145.52% YoY), and the FY2025 full-year result was $13.1 million, up 2309.27% from the prior year.
• Net Cash Flow retreated to -$6.5 million in Q1 2026, from -$3.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $11.3 million in Q1 2025 to a low of -$6.5 million in Q1 2026.
• A 5-year average of $1.1 million and a median of -$1.3 million in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 3252.37% in 2025, while the deepest fall reached 379.18% in 2025.
• Tracing NVCT's Net Cash Flow over 5 years: stood at -$3.6 million in 2022, then rose by 19.58% to -$2.9 million in 2023, then soared by 146.51% to $1.4 million in 2024, then sank by 379.18% to -$3.8 million in 2025, then plunged by 70.8% to -$6.5 million in 2026.
• Business Quant data shows NVCT's Net Cash Flow at -$6.5 million in Q1 2026, -$3.8 million in Q4 2025, and $8.6 million in Q3 2025.